


TAK-279 (NDI-034858)

TYK2

oral, once-daily, allosteric TYK2 inhibitor
Ph. IIb for moderate-to-severe plaque psoriasis
FEP+-supported core hopping + VLS
w/ TYK2-JH2 Xtal structure
Press release, March 18, 2023

NIMBUS THERAPEUTICS, MA / TAKEDA, JP




zavegepant

CGRP

CGRP receptor antagonist, first nasal spray
FDA-approved for acute migraines in adults
rational design based on known CGRP antagonists
FDA approval, March 10, 2023

BRISTOL MYERS SQUIBB, NY / PFIZER, INC., NY




revumenib

menin-KMT2A

oral menin-KMT2A inhibitor
Ph. I/II for r/r leukemia, CRC & solid tumors
discovery not disclosed
Nature, March 15, 2023

VITAE, MADISON, NJ / SYNDAX, WALTHAM, MA




zunsemetinib

MK2

oral p38 α -MK2 inhibitor
Ph. IIa for hidradenitis suppurativa (failed)
rational design from ATP-competitive molecule
Press release, March 6, 2023

CONFLUENCE, MO / ACLARIS THERAPEUTICS, PA




JNJ-1802

DENV

oral first-in-class DENV (NS3-NS4B) inhibitor
Ph. I for dengue
from a DENV-2 phenotypic antiviral screen
Nature, March 15, 2023

JANSSEN, BE + FR




nirogacestat

gamma secretase

oral gamma secretase inhibitor
Ph. III for DT/AF + Ph. II for OvGCTs
single-digit nanomolar potency for A β reduction in vitro
Press release, February 27, 2023 /
NEJM, March 9, 2023

PFIZER / SPRINGWORKS THERAPEUTICS, INC.




linvencorvir

HBV core protein

allosteric HBV modulator
Ph. II for chronic hepatitis B (CHB)
opt. of known allosteric heteroaryl pyrimidine
core protein modulator
J. Med. Chem., March 10, 2023

ROCHE, SHANGHAI, CN




KW-6356

A_{2A}R

oral A_{2A} receptor antagonist/inverse agonist
Ph. II for Parkinson's Disease
2nd gen. A_{2A} receptor antagonist
ASPET, March 9, 2023

KYOWA KIRIN CO., LTD., SHIZUOKA, JP




DKY709

IKZF2

oral IKZF2-selective molecular glue degrader
Ph. I/II for adv. solid tumors
opt. of pomalidomide analog
Cell Chemical Biology, March 1, 2023

NOVARTIS, CAMBRIDGE, MA



ACT-777991

CXCR3

oral reversible CXCR3 antagonist
Ph. I in healthy subjects
opt. of known CXCR3 antagonists
J. Med. Chem., March 8, 2023

IDORSIA PHARMACEUTICALS LTD, CH